BDTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Black Diamond Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$1.81+0.09 (+5.23%)
Close on Oct 19, 2026
- Market cap
- $103.83M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.20 (−54.86%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Black Diamond Therapeutics, Inc. saw revenue fall 100.0% to $0 over the twelve months to Jun 30, 2026. Operating income fell 1203.2% to -$51.90M.
Revenue
$0
-100.0% vs. a year earlier
Operating income
-$51.90M
-1203.2% vs. a year earlier
EPS, diluted
-$0.74
-421.7% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $103.83M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.08
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$42.56M
- EPS, diluted
- -$0.74
- Book value per share
- $1.68
- Diluted shares
- 57M
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
$0-100.0% YoY
Operating income
-$51.90M-1203.2% YoY
Net income
-$42.56M-394.7% YoY
EPS, diluted
-$0.74-421.7% YoY
Free cash flow
–
Reported periodTrailing twelve months